Phaseline

Companies › Aspa Therapeutics

Aspa Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV9 BBP-812
Adeno-associated virus serotype 9 (AAV9) delivering aspartoacylase (ASPA) gene
ASPAPhase 1Canavan DiseaseOct 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04998396AAV9 BBP-812Phase 1Canavan DiseaseMetabolic and endocrineOct 2032

Targets

ASPA (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.